Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

<Previous Article In Volume
Next Article In Volume>

The Differences of Programmed Death Ligand 1 Expression Between the Early Stages and Advanced Stages of Nasopharyngeal Carcinoma in DR. M Djamil Padang Hospital

Authors
Nadya Dwi Karsa1, 2, *, Sukri Rahman1, 2, Al Hafiz1, 2, Hirowati Ali3, Hafni Bachtiar4
1Department of Otorhinolaryngology Head & Neck Surgery of Faculty Medicine Andalas University, Indonesia
2Dr. M. Djamil General Hospital Padang, Indonesia
3Department of Biochemical Science of Faculty Medicine Andalas University, Indonesia
4Department of Public Health of Faculty Medicine Andalas University, Indonesia
*Corresponding author. Email: nadyadwikarsa@gmail.com
Corresponding Author
Nadya Dwi Karsa
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.010How to use a DOI?
Keywords
Nasopharyngeal carcinoma; PD-L1; PD-1; Immune checkpoint; immunotherapy
Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from the nasopharyngeal epithelial cells. Cell-mediated immunity has an important role in growth and development of cancer. Many studies have been conducted to predict the existence of an important relationship between immune checkpoints Programmed Death-1 (PD-1) and Programmed Death Ligand-1(PD-L1) with NPC. The research of checkpoint blocking antibodies against PD-1 and PD-L1 shows promising results for cancer immunotherapy. An analytical cross sectional study was conducted on 30 biological preparations for NPC patients consisting of 15 biological preparations for NPC patients with early stage and 15 biological preparations for NPC patients with advanced stages. Molecular examinations are carried out to see the expression of PD-L1 by the immunohistochemical (IHC) method on each of biological preparations,. Data were statistically analyzed with computer programs and were stated to be significant if p<0.05. In this study, a high PD-L1 expression was obtained in 3 of early stage NPC patients and 4 of advanced stage NPC patients using the Tumor Proportion Score assessment. Meanwhile, using the Immunoreactive Score assessment, a high PD-L1 expression was obtained in 1of early stage NPC patient and 4 of advanced stage NPC patients. Statistically, there was no significant difference in PD-L1 expression between early stage and advanced stage at NPC at Dr. M Djamil Padang Hospital with p> 0.05 A High PD-L1 expression was found to be more prevalent in the advanced stage of NPC patient but there was no significant difference in PD-L1 expression between early stage and advanced stage at NPC at Dr. M Djamil Padang Hospital

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
10.2991/ahsr.k.220206.010
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.010How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Nadya Dwi Karsa
AU  - Sukri Rahman
AU  - Al Hafiz
AU  - Hirowati Ali
AU  - Hafni Bachtiar
PY  - 2022
DA  - 2022/02/21
TI  - The Differences of Programmed Death Ligand 1 Expression Between the Early Stages and Advanced Stages of Nasopharyngeal Carcinoma in DR. M Djamil Padang Hospital
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 44
EP  - 50
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.010
DO  - 10.2991/ahsr.k.220206.010
ID  - Karsa2022
ER  -